Levosimendan use in several scenarios of acute heart failure.
In countries where it is available, early levosimendan infusion can be considered for patients who remain symptomatic with dyspnea at rest despite initial therapy, particularly those with a history of chronic heart failure or chronically treated with beta-blockers. Hypotensive patients or patients with active ischemia are not the best candidates for levosimendan administration and should have these problems addressed first.
Tavares
Miguel
M
Department of Anesthesiology and Critical Care, Hospital Geral de Santo António, Porto - Portugal.
Andrade
Ana Carolina
AC
Mebazaa
Alexandre
A
D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000075202:Contraindications; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage / Q000627:therapeutic use*; D007022:Hypotension / Q000150:complications; D007511:Ischemia / Q000150:complications; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects; D011724:Pyridazines / Q000008:administration & dosage / Q000627:therapeutic use*; D000077464:Simendan; D013577:Syndrome; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D002316:Cardiotonic Agents; D006835:Hydrazones; D010726:Phosphodiesterase Inhibitors; D011724:Pyridazines; D014665:Vasodilator Agents; D000077464:Simendan